Skip to main content
. 2019 Jan 13;185(1):89–92. doi: 10.1111/bjh.15749

Figure 1.

Figure 1

Probability of survival following MSC treatment. (A) Probability of survival of the whole cohort of patients. (B) Probability of survival of responders and non‐responders. log‐rank test, P < 0.0001; hazard ratio: 0·2. Median survival in responders was not reached, while it was 20 days (95% CI 11–29 days) in non‐responders. Overall survival estimates start from mesenchymal stromal cell (MSC) infusion.